rs751904543
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PP5_Very_Strong
The NM_004168.4(SDHA):c.1663+3G>C variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000137 in 1,611,152 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_004168.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SDHA | NM_004168.4 | c.1663+3G>C | splice_region_variant, intron_variant | ENST00000264932.11 | NP_004159.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SDHA | ENST00000264932.11 | c.1663+3G>C | splice_region_variant, intron_variant | 1 | NM_004168.4 | ENSP00000264932.6 | ||||
ENSG00000286001 | ENST00000651543.1 | n.*396+3G>C | splice_region_variant, intron_variant | ENSP00000499215.1 |
Frequencies
GnomAD3 genomes AF: 0.0000328 AC: 5AN: 152212Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251132Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135716
GnomAD4 exome AF: 0.0000117 AC: 17AN: 1458940Hom.: 0 Cov.: 30 AF XY: 0.0000152 AC XY: 11AN XY: 725850
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152212Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74368
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | May 25, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Sep 11, 2024 | The SDHA c.1663+3G>C variant has been reported in the published literature in individuals with gastrointestinal stromal tumors (PMIDs: 23060355 (2015) and 35059314 (2021)), as well as in individuals with paragangliomas (PMID: 30877234 (2019)). A functional study demonstrated that abnormal splicing led to skipping of exon 12 (PMID: 30877234 (2019)). The frequency of this variant in the general population, 0.000097 (3/30876 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant may affect proper SDHA mRNA splicing. Based on the available information, this variant is classified as likely pathogenic. - |
Paragangliomas 5;C5700310:Mitochondrial complex II deficiency, nuclear type 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change falls in intron 12 of the SDHA gene. It does not directly change the encoded amino acid sequence of the SDHA protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs751904543, gnomAD 0.006%). This variant has been observed in individuals with gastrointestinal stromal tumor and paraganglioma (PMID: 23060355, 30877234; Invitae). ClinVar contains an entry for this variant (Variation ID: 577461). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 12 and introduces a premature termination codon (Invitae). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 14, 2023 | The c.1663+3G>C intronic variant results from a G to C substitution 3 nucleotides after coding exon 12 in the SDHA gene. This alteration has been detected in two individuals with a paraganglioma; tumor analyses showed the presence of a somatic pathogenic SDHA mutation and/or loss of SDHA and SDHB by immunohistochemistry (Ben Aim L et al. J Med Genet, 2019 08;56:513-520). In addition, this variant was identified in a gastrointestinal stromal tumor with negative SDHA immunostaining, as well as non-neoplastic tissue of the same patient (Dwight T et al. Am J Surg Pathol, 2013 Feb;37:226-33). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing (Ben Aim L et al. J Med Genet, 2019 08;56:513-520; Ambry internal data). Another alteration impacting the same donor site (c.1663+1G>T) has been shown to have a similar impact on splicing and has also been reported in an individual with a gastrointestinal stromal tumor (Ambry internal data). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
SDHA-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 08, 2024 | The SDHA c.1663+3G>C variant is predicted to interfere with splicing. This variant has been reported in individuals with gastrointestinal stromal tumors and individuals with paragangliomas (Dwight et al. 2013. PubMed ID: 23060355; Pantaleo et al. 2022. PubMed ID: 35059314; Ben Aim et al. 2019. PubMed ID: 30877234). This variant is reported in 0.0054% of alleles in individuals of East Asian descent in gnomAD. This variant is predicted to alter canonical splice site by all splicing prediction programs (Alamut Visual Plus v1.6.1). RNA study suggests this variant results in abnormal splicing (Ben Aim et al. 2019. PubMed ID: 30877234). This variant is interpreted as pathogenic, likely pathogenic or a variant of uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/577461/). This variant is interpreted as likely pathogenic. - |
Paragangliomas 5 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Feb 08, 2024 | This variant is considered likely pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 30877234, 35059314]. mRNA analysis has demonstrated abnormal mRNA splicing occurs [PMID: 30877234]. - |
Gastrointestinal stromal tumor Uncertain:1
Uncertain significance, flagged submission | research | “Giorgio Prodi” Cancer Research Center, University of Bologna | Oct 01, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at